Source: Biothera
Posted: November 21, 2006
Summary:
Biothera, a biotechnology company dedicated to improving immune health, announced it has begun a Phase I/II clinical trial to test the effects of its lead drug compound Imprime PGG used with in combination with another drug, G-CSF, to help move bone-marrow stem cells into the blood. The full news release can be found here:
No comments:
Post a Comment